FULGENT GENETICS, INC. Debt Securities, Available-for-sale, Amortized Cost
FULGENT GENETICS, INC. (FLGT) had Debt Securities, Available-for-sale, Amortized Cost of $814.51 million as of 2022-12-31, per its 10-Q filed 2023-11-03.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-11-03
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $814.51M.
- 2020-09-30: Debt Securities, Available-for-sale, Amortized Cost $50.16M.
- 2020-06-30: Debt Securities, Available-for-sale, Amortized Cost $62.90M.
- 2020-03-31: Debt Securities, Available-for-sale, Amortized Cost $61.53M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-12-31 | $814.51M 10-Q · filed 2023-11-03 |
| 2020-09-30 | $50.16M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $62.90M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $61.53M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $58.12M 10-Q · filed 2020-11-09 |
| 2019-09-30 | $22.92M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $29.37M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $33.10M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $30.78M 10-K · filed 2020-03-13 |
| 2018-09-30 | $28.48M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $34.59M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $34.63M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $35.04M 10-K · filed 2019-03-22 |
| 2017-09-30 | $34.52M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $34.75M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $40.41M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $38.73M 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |